Psyched Wellness included in high-profile AdvisorShares Psychedelics Exchange Traded Fund

Psyched Wellness Ltd., a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, said it has been included in the new AdvisorShares Psychedelics Exchange Traded Fund (ETF).

Listed on the NYSE Arca, previously known as ArcaEx, under the ticker symbol PSIL, the ETF currently includes 23 psychedelics companies and actively manages investments in the emerging psychedelic drugs sector. The ETF offers exposure to those biotechnology, pharmaceutical and life sciences companies that AdvisorShares sees as leading the psychedelics industry.

In a statement, Psyched Wellness CEO Jeffrey Stevens said: “Psyched’s inclusion in the AdvisorShares Psychedelics Exchange Traded Fund acknowledges the important research and product development the company is doing on its proprietary extract of Amanita Muscaria, AME-1.”

READ: Psyched Wellness initiates clinical sleep study on humans for structure/function claim for its AME-1 extract

“We believe AME-1 has the power to help people achieve stress relief, relaxation and restful sleep. We are grateful that the ongoing work at Psyched has been recognized by AdvisorShares and we are among the leaders in the psychedelics industry.”

Psyched Wellness is a Toronto, Canada-Based health supplements company focused on the distribution of mushroom-derived products and associated consumer packaged goods. The firm aims to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

The company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Story by ProactiveInvestors